Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

BRAF V600E Mutation 1

Interventions

Magnetic Resonance Spectroscopy 17Cyclophosphamide 16fludarabine 12Specimen Handling 12Fluorodeoxyglucose F18 7pembrolizumab 6X-Rays 6Nivolumab 6Temozolomide 5Radiotherapy 5Immunotherapy, Adoptive 5lenvatinib 4Paclitaxel 4Leukapheresis 4Immune Checkpoint Inhibitors 4Etoposide 4Cisplatin 4Carboplatin 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4ruxolitinib 3fluciclovine F-18 3Tirzepatide 3Surgical Procedures, Operative 3Doxorubicin 3Dasatinib 3Cholecalciferol 3Biopsy 368Ga-FAPI 3tislelizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Cobicistat × Clear all
NCT06610682 2025-12-10

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
15 enrolled

BRAF V600E Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡